BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma announces FDA acceptance of dersimelagon NDA with Priority Review and closes acquisition from Tanabe Pharma.
Danish drugmaker LEO Pharma said on Tuesday it had agreed to acquire worldwide rights to drug candidate dersimelagon from Tanabe Pharma for up to $435 million in up-front and near-term milestone payments.
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.